PCI Biotech appoints Dr Amir Snapir as Chief Medical Officer
31 mars 2020 02h00 HE
|
PCI Biotech Holding ASA
Oslo, Norway, 31 March 2020 - PCI Biotech announces the appointment of Dr Amir Snapir, MD, PhD as Chief Medical Officer (CMO). Dr Snapir will also serve as a member of PCI Biotech’s executive...
PCI Biotech: US patent for the vaccine technology (fimaVacc) with a new important class of adjuvants
26 mars 2020 04h12 HE
|
PCI Biotech Holding ASA
Oslo (Norway), 26 March 2020 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announces that the U.S. Patent and Trademark Office (USPTO) has informed the company that a...
PCI Biotech: Update on operational implications of the corona pandemic
25 mars 2020 05h06 HE
|
PCI Biotech Holding ASA
Oslo, Norway, 25 March, 2020: PCI Biotech (OSE: PCIB) has closely monitored potential implications on its short- and long-term operations following the latest development of the coronavirus pandemic....
PCI Biotech's fourth quarter and preliminary 2019 results
26 févr. 2020 01h00 HE
|
PCI Biotech Holding ASA
Oslo (Norway), 26 February 2020 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announces its interim fourth quarter and preliminary 2019 results. Please find enclosed the...
PCI Biotech: Invitation to fourth quarter and preliminary 2019 results presentation
19 févr. 2020 07h38 HE
|
PCI Biotech Holding ASA
Oslo, Norway, 19 February 2020 - PCI Biotech invites to a presentation of the company's fourth quarter and preliminary 2019 results on Wednesday 26 February 2020 at Oslo Cancer Cluster Innovation...
PCI Biotech: US patent granted for the vaccine technology (fimaVacc) in combination with cytokines
21 janv. 2020 02h00 HE
|
PCI Biotech Holding ASA
Oslo (Norway), 21 January 2020 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announces that the U.S. Patent and Trademark Office (USPTO) has granted the company a US...
PCI Biotech to present Phase I fimaVacc results at ESMO Immuno-Oncology 2019
12 déc. 2019 02h00 HE
|
PCI Biotech Holding ASA
Oslo, Norway, December 12, 2019 PCI Biotech (OSE:PCIB), a clinical-stage company developing innovative therapeutics that address significant unmet medical needs, today announced that it will present...
PCI Biotech: Third quarter 2019 results
27 nov. 2019 01h00 HE
|
PCI Biotech Holding ASA
Oslo (Norway), 27 November 2019 - PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company today announces its third quarter 2019 result. Please find enclosed the report and presentation. ...
PCI Biotech: Expansion of preclinical research collaboration agreement with AstraZeneca
26 nov. 2019 12h10 HE
|
PCI Biotech Holding ASA
Oslo (Norway), 26 November 2019 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announced an expansion of its preclinical research collaboration with AstraZeneca. The...
PCI Biotech to present at Jefferies 2019 London Healthcare Conference
19 nov. 2019 09h00 HE
|
PCI Biotech Holding ASA
Oslo, Norway, November 19, 2019 PCI Biotech (OSE:PCIB), a late stage clinical company developing innovative therapeutics that address significant unmet medical needs, today announced that it will...